Total Payments
$10,156
2024 Payments
$1,495
Companies
74
Transactions
428
Medicare Patients
8,587
Medicare Billing
$6.9M
Payment Breakdown by Category
Food & Beverage$7,226 (71.1%)
Gifts$1,595 (15.7%)
Education$1,136 (11.2%)
Other$199.40 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,226 | 381 | 71.1% |
| Gift | $1,595 | 19 | 15.7% |
| Education | $1,136 | 26 | 11.2% |
| Long term medical supply or device loan | $199.40 | 2 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,069 | 37 | $0 (2024) |
| Janssen Biotech, Inc. | $804.66 | 63 | $0 (2024) |
| PFIZER INC. | $486.97 | 41 | $0 (2024) |
| Celgene Corporation | $433.08 | 14 | $0 (2024) |
| Pharmacyclics LLC, an AbbVie Company | $408.51 | 10 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $370.12 | 20 | $0 (2024) |
| Astellas Pharma US Inc | $324.55 | 11 | $0 (2022) |
| Seagen Inc. | $292.68 | 8 | $0 (2023) |
| Genentech USA, Inc. | $290.33 | 13 | $0 (2024) |
| ABBVIE INC. | $266.53 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,495 | 56 | Novartis Pharmaceuticals Corporation ($271.61) |
| 2023 | $1,197 | 46 | Seagen Inc. ($192.90) |
| 2022 | $1,158 | 47 | ABBVIE INC. ($147.75) |
| 2021 | $1,193 | 70 | Janssen Biotech, Inc. ($132.77) |
| 2020 | $1,213 | 43 | Novartis Pharmaceuticals Corporation ($614.70) |
| 2019 | $2,289 | 96 | Novartis Pharmaceuticals Corporation ($1,037) |
| 2018 | $791.48 | 33 | Pharmacyclics LLC, An AbbVie Company ($219.31) |
| 2017 | $819.64 | 37 | Celgene Corporation ($170.50) |
All Payment Transactions
428 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $24.80 | General |
| 12/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/26/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $34.02 | General |
| Category: DESMOID TUMORS | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $5.23 | General |
| Category: Oncology | ||||||
| 11/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/13/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $24.07 | General |
| 11/06/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: Bone Health | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug), DARZALEX | Food and Beverage | In-kind items and services | $40.02 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $29.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/02/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $31.01 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.80 | General |
| Category: Hematology/Oncology | ||||||
| 08/27/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 07/31/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Myriad Genetic Laboratories, Inc. | BRACANALYSIS CDX (Device) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,530 | 91,074 | $8.5M | $2.0M |
| 2022 | 40 | 2,162 | 82,972 | $9.2M | $1.8M |
| 2021 | 37 | 2,171 | 59,248 | $7.0M | $1.7M |
| 2020 | 32 | 1,724 | 79,510 | $4.5M | $1.4M |
Total Patients
8,587
Total Services
312,804
Medicare Billing
$6.9M
Procedure Codes
152
All Medicare Procedures & Services
152 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 22,000 | $3.6M | $951,957 | 26.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 57 | 16,440 | $1.1M | $303,195 | 26.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 108 | 140 | $704,087 | $190,784 | 27.1% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 16 | 153 | $348,109 | $74,617 | 21.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 92 | 639 | $267,373 | $71,166 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 352 | 707 | $275,002 | $70,999 | 25.8% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 11 | 480 | $251,290 | $48,813 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 175 | 316 | $172,618 | $44,292 | 25.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 106 | 138 | $149,365 | $37,845 | 25.3% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 23 | 81 | $109,347 | $28,593 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 136 | 136 | $87,859 | $22,399 | 25.5% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 14 | 15 | $71,777 | $20,746 | 28.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 170 | 224 | $60,547 | $15,706 | 25.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 81 | 614 | $56,714 | $15,091 | 26.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 15 | 91 | $43,020 | $13,345 | 31.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 42 | 219 | $45,078 | $11,981 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 107 | $37,344 | $10,382 | 27.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 63 | 349 | $31,481 | $8,250 | 26.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 125 | $26,124 | $6,778 | 25.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 74 | 483 | $25,305 | $6,296 | 24.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 41 | $21,069 | $5,799 | 27.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 108 | 502 | $23,286 | $5,795 | 24.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 72 | $16,551 | $4,645 | 28.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $16,073 | $4,333 | 27.0% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 19 | 81 | $14,019 | $3,852 | 27.5% |
About Dr. Aminder Mehdi, MD
Dr. Aminder Mehdi, MD is a Specialist healthcare provider based in Stockton, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780612507.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aminder Mehdi, MD has received a total of $10,156 in payments from pharmaceutical and medical device companies, with $1,495 received in 2024. These payments were reported across 428 transactions from 74 companies. The most common payment nature is "Food and Beverage" ($7,226).
As a Medicare-enrolled provider, Mehdi has provided services to 8,587 Medicare beneficiaries, totaling 312,804 services with total Medicare billing of $6.9M. Data is available for 4 years (2020–2023), covering 152 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Stockton, CA
- Active Since 06/29/2006
- Last Updated 03/09/2020
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1780612507
Products in Payments
- KISQALI (Drug) $1,759
- Imbruvica (Drug) $378.51
- IBRANCE (Drug) $259.06
- BRUKINSA (Drug) $205.57
- OPDIVO (Biological) $205.11
- DARZALEX (Biological) $204.53
- ERLEADA (Drug) $198.16
- Cabometyx (Drug) $190.97
- IMBRUVICA (Drug) $180.91
- KEYTRUDA (Biological) $177.08
- VENCLEXTA (Drug) $172.07
- Trodelvy (Drug) $164.58
- RYBREVANT (Drug) $157.06
- LIBTAYO (Biological) $154.40
- VERZENIO (Drug) $133.82
- SARCLISA (Biological) $111.80
- JAKAFI (Drug) $99.80
- Revlimid (Drug) $98.06
- MEKINIST (Drug) $82.83
- Epkinly (Drug) $79.53
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Stockton
Gregory Bensch, M.d, M.D
Specialist — Payments: $1.8M
Specialist $1.8M
George Bensch, M.d, M.D
Specialist — Payments: $144,679
Specialist $144,679
Dr. Ajithkumar Puthillath, Md, MD
Specialist — Payments: $33,046
Specialist $33,046
Prasad Dighe, Md, MD
Specialist — Payments: $13,978
Specialist $13,978
Josebelo Chong, Md, MD
Specialist — Payments: $7,732
Specialist $7,732
Dean Karnaze, Md, MD
Specialist — Payments: $5,510
Specialist $5,510